9 Facts About Low-Dose Naltrexone as a Menopause Treatment Option
There's something quietly frustrating about discovering a treatment that has years of safety data and a plausible mechanism — and then realising most doctors have never considered it for menopause. If you've been told your options are hormones or 'just manage it,' knowing LDN exists feels like finding a door that was always there but never pointed out.
Learn more about Rose →Naltrexone at standard doses is an opioid blocker — low-dose naltrexone is something different entirely
Full-dose naltrexone (50mg) is an FDA-approved opioid antagonist used in addiction medicine. Low-dose naltrexone (LDN) sits between 1.5mg and 4.5mg daily — a range where it appears to work through a completely different mechanism, briefly blocking opioid receptors rather than occupying them continuously. That transient blockade is thought to trigger a rebound upregulation of the body's own endorphin system, which is where its relevance to menopause begins.
The endorphin connection makes LDN physiologically relevant to hot flashes
Hot flashes are driven in large part by oestrogen's withdrawal from the hypothalamic thermoregulatory system, which depends heavily on endogenous opioid tone — specifically beta-endorphin. When oestrogen drops, so does beta-endorphin activity, destabilising the brain's narrow temperature comfort zone. LDN's proposed mechanism of boosting endogenous opioid production means it is targeting the same physiological pathway disrupted by falling oestrogen, not simply masking symptoms.
A small but well-designed trial found LDN meaningfully reduced hot flash frequency
A 2023 randomised controlled trial published in Menopause found that women taking low-dose naltrexone experienced a statistically significant reduction in hot flash frequency compared to placebo over eight weeks. The effect size was modest but clinically meaningful, particularly for women who reported moderate to severe flashes. It was a small trial and needs replication, but it was rigorous — randomised, blinded, and placebo-controlled.
LDN has an established track record in chronic pain conditions, which matters for menopause-related pain
Fibromyalgia, vulvodynia, and musculoskeletal pain all become more common around menopause, and LDN has more robust evidence in chronic pain than it does specifically in menopause. Studies in fibromyalgia show reductions in pain scores and fatigue, thought to relate to LDN's anti-neuroinflammatory effects via microglial modulation. For women whose menopause presentation is dominated by body pain, this broader evidence base is worth knowing about.
Its proposed anti-inflammatory mechanism may also explain potential mood benefits
LDN appears to reduce neuroinflammation by transiently blocking toll-like receptor 4 on microglial cells in the brain — cells that become more activated when oestrogen declines. Neuroinflammation is increasingly implicated in the low mood, irritability, and anxiety that track with perimenopause. While no large trials have tested LDN specifically for perimenopausal mood, the biological rationale is coherent and early data from depression research is cautiously encouraging.
The side effect profile at low doses is generally mild and time-limited
The most commonly reported side effect of LDN is vivid dreams or mild sleep disruption, particularly in the first one to two weeks, which is why many prescribers recommend taking it in the morning rather than at night. Nausea is occasionally reported but tends to resolve quickly. Because the dose is so far below standard naltrexone dosing, the significant side effects associated with full-dose opioid blockade are not typically seen.
LDN cannot be used by anyone taking opioid pain medication — this is a hard contraindication
Because naltrexone blocks opioid receptors, taking it alongside opioid-based pain medication will precipitate acute withdrawal, which can be severe. This is not a precaution to weigh up — it is an absolute contraindication. Women managing chronic pain conditions with opioid medications need to know this clearly before pursuing LDN as an option.
LDN is off-label for menopause everywhere in the world, which shapes how accessible it is
Naltrexone has no regulatory approval specifically for menopause symptoms in any country, meaning prescriptions are written off-label and the medication is typically compounded by a specialist pharmacy rather than dispensed as a standard commercial product. Insurance coverage is inconsistent and in many healthcare systems patients pay out of pocket. The off-label status does not mean it is experimental in a worrying sense — it simply means the pharmaceutical approval pathway has not been pursued.
LDN is most likely to be discussed as a complement to other treatments, not a replacement for them
For women who can use hormone therapy, LDN is not positioned as an alternative — the evidence base for HRT remains far stronger across the full range of menopause symptoms. Where LDN becomes more relevant is for women who cannot use hormones, who have residual symptoms despite HRT, or who are managing overlapping conditions like chronic pain or autoimmune disease. Thinking of it as one potential tool in a broader symptom management plan is more realistic than expecting it to function as a standalone solution.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.